UNSPSC 51142310: Nalmefene hydrochloride

This classification denotes an opiate antagonist with the molecular formula C21H25NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7K69QC05X, chemically known as 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol,, hydrochloride but more generally known as nalmefene hydrochloride, which bears US NIH Compound Identifier 5388881. European Medicines Agency schedules Nalmefene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14628MIG.

UNSPSC 51142310 Nalmefene hydrochloride is a Commodity code that reflects state and local procurement of opioid-antagonist medications and related drug-response products for public health and emergency-response programs. Recent solicitations show issuing bodies purchasing naloxone (a nalmefene-class opioid antagonist) alongside ancillary drug-deactivation systems to support community health initiatives, overdose-response capacity, and pharmacy benefit management at the state and regional level. Buyers include county health departments and state health and human services agencies. The code encompasses not only the active pharmaceutical ingredient but the finished pharmaceutical products and related systems that public bodies deploy in overdose-response, emergency medical, and controlled substance-management contexts.

Geographic activity centers on Florida and Minnesota, with Texas state health agencies also active in the space. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, with a due date of July 26, 2023 (note: due date appears to be a data error in the source, as the posting date is June 30, 2026). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for direct-to-manufacturer prescription programs supporting the state's pharmacy benefit objectives, reflecting early-stage procurement planning rather than immediate opportunity. Vendors pursuing these opportunities face standard state and local contracting requirements including E-Verify compliance, insurance coverage (workers' compensation, commercial general liability, and professional liability), cGMP and drug-supply-chain-security certifications, and performance metrics tied to delivery timelines and administrative compliance.